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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Little is understoodabout the clinical course andprognosis of patientswith
Sauropus androgynus-related obstructive lung disease. The aim of this study was to investigate
their clinical manifestations and pulmonary function change 15 years after the acute episode.
Methods: A descriptive, observational study of patients with S androgynus-related obstructive
lung disease, diagnosed 15 years ago, was conducted. We evaluated their pulmonary function
and the Modified Medical Research Council (MMRC) dyspnea scale. Saint George’s Respiratory
Questionnaire (SGRQ) was also performed. Age- and forced expiratory volume in one second
(FEV1)-matched chronic obstructive pulmonary disease (COPD) patients were used as a reference
group for comparison of clinical manifestations.
Results: Twenty-nine of 49 patients, diagnosed at our hospital 15 years ago, could be contacted.
Four patients died and one patient was ventilator-dependent. Sixteen patients were willing to
come to our hospital to have pulmonary function and questionnaire evaluation. The FEV1 of these
patients declined only 1.6 21.6mL/year over a 15-year period. Meanwhile, the severity of their
dyspnea and their health-related quality of life were better than age- and FEV1-matched COPD
patients as shown by the MMRC dyspnea scale (1.4  0.8 vs. 2.0  1.0; pZ 0.037) and symptom
domain of the SGRQ (32.6  18.4 vs. 43.5  20.3; pZ 0.006).
Conclusion: After an acute deterioration, patients with S androgynus-related obstructive lung
disease had a stationary pulmonary function over a period of 15 years, and their clinical manifes-
tations were less severe than age- and FEV1-matched COPD patients. A further study with a larger
sample size may be needed to confirm these findings.
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S. androgynus-related obstructive lung disease 631IntroductionSauropusandrohynus, aMalaysian leaf vegetable, isamember
of the Euphorbiacae family and a perennial shrub. It has been
used for weight control by young and middle-aged women.
S. androgynus intoxicationwas first detected inAugust 1994 in
Taiwan,1,2 and another small group of patients was also re-
ported in Japan in 2005.3 Forty-nine patients were diagnosed
with S. androgynus-related obstructive lung disease in our
hospital during that outbreak, and a dose-response relation-
ship of lung function impairment was determined by Hsiue
etal.4 Patientspresentedwithprogressive respiratorydistress
and eventually irreversible respiratory failure, similar to
clinical manifestations in other obstructive lung diseases. The
association between obstructive lung disease and S. andro-
gynuswas documented in the 1990s in epidemiologic studies,5
and many studies have described the clinical features and
pathogenesis of this disease entity.6,7 However, there has
been no report about long-term follow-up of the change of
pulmonary function in patients with S. androgynus-related
obstructive lung disease. The aim of this study was to
contact the 49 patients diagnosed with S. androgynus-related
obstructive lung disease, and an observational study was
designed toevaluate thecurrent general status andchanges in
lung function of these patients 15 years later.
Materials and methods
Patient group
In 1995, an outbreak of S. androgynus-related obstructive
lung disease occurred in southern Taiwan and Japan. Forty-
nine patients with a history of consumption of this vege-
table were diagnosed with obstructive lung disease in our
hospital. In late 2010, we attempted to contact these
patients and investigated their current clinical symptoms
and pulmonary function. In these 49 patients, 29 patients
could be contacted. In these 29 patients, four patients died
and one patient was ventilator-dependent, and 16 patients
were willing to come to our hospital to have pulmonary
function and questionnaire evaluations. The investigation
protocol was approved by National Cheng Kung University
Hospital’s ethics committee, and informed consent was
obtained from each patient.
Reference group
Thirty-two patients, who were matched for age and lung
function with the patients under investigation, were
recruited from the outpatient clinic. All patients had
moderate-to-severe chronic obstructive pulmonary disease
(COPD) according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines. Baseline vari-
ables, including age, gender, Charlson co-morbidities index
and % predicted of forced expiratory volume in one second
(FEV1 %) predicted were recorded. Patients, who were
incapable of completing the questionnaire and those with
aCharlson co-morbidities index8 higher than 2wereexcluded
to avoid the impact of co-morbidities on life quality. Signed
informed consent was obtained from all patients.Pulmonary function tests
Spirometry and lung volumes (helium dilution method)
were performed with a rolling seal spirometer (Chestec 65;
Chest Co., Tokyo, Japan) according to standard methods
suggested by the American Thoracic Society.9
Questionnaires
The Modified Medical Research Council (MMRC) dyspnea
scale10 and Saint George’s Respiratory Questionnaire
(SGRQ)11 were used to assess the functional status and
quality of life of each patient and were recorded by
a trained technician in the pulmonary function laboratory.
Statistical analysis
Data were presented as mean  SD. A paired t test was used
to compare changes in pulmonary function and the body
mass index (BMI) between the initial diagnosis and follow-
up period. The Mann-Whitney U test was used for discrim-
ination of quality of life between the patient and reference
groups. Fisher’s exact test was used to compare nominal
variables between groups. The doseeeffect on the
obstructive impairment of lung function was assessed using
Spearman’s correlation analysis. A p value of <0.05 was
considered significant. Statistical analyses were performed
using GraphPad Prism 5 for Windows 7 version.
Results
Twenty-nine patients with a previous diagnosis of S. andro-
gynus-related obstructive lung disease or their families
were available for contact in this study. Among these 29
patients, four patients had died and one patient was
ventilator-dependent and lives in a respiratory care ward.
The causes of death in these four patients were three from
respiratory complications within 5 years after ingestion of
S. androgynus (3, 4, and 4.5 years) and one from pancreatic
cancer 10 years after ingestion of S. androgynus. One
patient was ventilator-dependent 3 years after the initial
consumption of S. androgynus and 2 years after the diag-
nosis of S. androgynu-related obstructive lung disease.
Sixteen of the 24 surviving patients were willing to come to
our hospital for pulmonary function test and interview, and
their data were analyzed. Only one patient was a man, and
none of them had a history of smoking, autoimmune
disease, or inhalation injury before or after S. androgynus
consumption. All 16 patients completed pulmonary function
tests and the MMRC and SGRQ questionnaires.
Characteristics of these 16 patients are listed in Table 1.
Components of the SGRQ, including symptom, activity and
impact scores, were recorded (Table 2). The initial lung
function test was performed while patients were suspicious
of having S. androgynus-related obstructive lung disease
from clinical history and symptoms. The duration from the
beginning of S. androgynus consumption to the diagnosis of
lung disease using pulmonary function test (PFT) as a diag-
nostic tool was 7 months in average. Data including lung
function with the % predicted of total lung capacity (TLC %
Table 1 Characteristics of 16 patients with a diagnosis of Sauropus androgynus-associated obstructive lung disease.
Patient no. Age (y) Sex BMI Total amounts (g) MMRC SGRQ total
1 50 F 19.6 3600 3 75.1
2 75 F 38.4 4200 2 23.0
3 69 F 25.2 4800 1 18.0
4 70 F 34.2 6000 2 65.8
5 62 F 26.7 5400 1 24.7
6 62 F 22.7 1500 0 48.8
7 66 F 23.0 2700 1 28.7
8 66 F 22.7 3600 1 38.1
9 60 F 19.4 13,500 3 36.1
10 61 F 21.1 10,800 1 9.4
11 78 F 20.8 3000 1 36.9
12 71 F 21.6 9000 1 12.6
13 58 F 27.3 3300 1 21.1
14 65 M 26.0 9000 1 27.0
15 55 F 21.9 6000 1 41.7
16 55 F 36.3 4500 2 14.9
Mean  SD 64.5  7.6 25.4  5.9 5681  3285 1.4  0.8 32.6  18.4
BMI Z body mass index; MMRC Z Modified Medical Research Council; SGRQ Z Saint George’s Respiratory Questionnaire.
632 C.-Y. Ou et al.predicted), FEV1/forced vital capacity ratio (FEV1/FVC
ratio), FEV1, FEV1% predicted, FVC, FVC % predicted, SpO2
and BMI were compared between initial and recent periods
(Table 3). There were no significant declines in lung func-
tion and BMI during the follow-up period 15 years after
consumption of S. androgynus. The FEV1 decline in the past
15 years was only e1.6G21.6 mL/year (Fig. 1). And these
patients also showed a higher percent predicted of TLC and
percent predicted of FVC compared with initial lung func-
tion (p < 0.0001 and p Z 0.0006 respectively).
Evaluating the current health-related quality of life in
our patients was the second aim of our study. We compared
our patient group with an age- and FEV1-matched reference
group, and we found that the patient group had less severe
dyspnea and better health-related quality of life than the
COPD patients on the MMRC dyspnea scale and symptom
domain of the SGRQ (Table 4). However, the Charlson index
was higher in reference group.Table 3 Results of pulmonary function test and BMI
compared at different times.
Initial diagnosis Follow-up p value
TLC % predicted 94.8  20.3 116.2  19.8 <0.0001
FEV1/FVC(%) 51.4  10.6 46.7  11.6 nsDiscussion
The diagnosis of S. androgynus-induced obstructive lung
disease can be made clinically when there is a history of
S. androgynus consumption, no chronic respiratory disease,
obstructive ventilation without bronchodilator response,
bilateral bronchiectasis, and patchy low attenuation of lung
parenchyma with mosaic perfusion on high-resolution CT.Table 2 Individual SGRQ scores in 16 patients.
SGRQ symptoms SGRQ activity SGRQ impacts
Scores 23.8  18.3 48.6  22.0 26.3  21.7
Data are presented as mean  SD. SGRQ Z Saint George’s
Respiratory Questionnaire.An in vitro study7 showed that apoptosis and necrosis are
involved in the toxicity of S. androgynus and T-cell medi-
ated immunity is predominant in the pathogenesis.2,12
Histopathological findings included constrictive oblitera-
tive bronchitis/bronchiolitis resulting eventually in irre-
versible fibrosis of the small bronchi and the bronchioles.13
A hospital-based case-control study5 showed that larger
total amounts of S. androgynus and preparation methods
that did not include cooking were significant risk factors for
lung disease. Corticosteroid therapy is not effective14 and
the only treatment is lung transplantation.15 In a short-term
follow-up study,4 the major symptom of this disease,
dyspnea, developed within 7 months after consumption of
the vegetable and obstructive ventilatory defects were
irreversible during the observation period of 22 months.
There has been no long-term follow-up study of patients
diagnosed in the outbreak of 1995. The aim of this study
was to focus on the changes in pulmonary function and
quality of life 15 years after S. androgynus-induced lung
injury. In that outbreak of 1995, PFT was performed in ourFEV1 (L) 1.0  0.3 1.0  0.5 ns
FEV1 % predicted 43.9  14.1 50.9  19.7 ns
FVC (L) 2.0  0.7 2.2  0.7 ns
FVC % predicted 74.6  19.9 87.6  23.8 0.0006
BMI 26.6  5.6 25.4  5.9 ns
SpO2 95.7  1.3 95.3  2.1 ns
Data are presented as mean  SD. TLC Z total lung capacity;
FEV1 Z forced expiratory volume in 1 second; FVC Z forced
vital capacity; BMI Z body mass index.
Figure 1 Follow-up FEV1 in 16 patients with Sauropus
androgynus-induced obstructive ventilatory defects.
S. androgynus-related obstructive lung disease 633patients with history of consumption of S. androgynus and
presentation of respiratory distress. The initial PFT was
defined as the first time of examination while diagnosis of
S. androgynus-induced obstructive lung disease, and the
average duration from consumption to diagnosis was 7
months. Four patients suffered from acute or chronic
respiratory failure (three dead and one dependent on
ventilator) within 5 years, indicating that the disease has an
initial rapid downhill course in some patients. However,
survivors of the acute phase, after a period of 15 years,
follow-up spirometry showed moderative to severe
obstructive ventilatory defects without significant differ-
ence from their initial lung function. After a period of 15
years follow-up, most of our patients were in a stationary
status after the initial deterioration of their pulmonary
function. This is in contrast to COPD patients, which is
characterized by progressive deterioration in physiologicTable 4 Comparison of life quality between reference
and investigating groups.
Patient groups Reference
(COPD)
Investigating
(S. androgynus-
related
obstructive
lung disease)
p value
Age (y) 64.7  11.1 64.5  7.6 0.5470
Sex (F/M) 13/19 15/1 0.0005*
Smoking status Ex-smokers Non-smokers
FEV1 % predicted 46.4  15.0 50.9  19.7 0.4569
Charlson index 1.6  0.8 0.3  0.4 <0.0001*
MMRC 2.0  1.0 1.4  0.8 0.0369*
SGRQ total 41.6  20.5 32.6  18.4 0.1355
SGRQ symptoms 43.5  20.3 23.8  18.3 0.0055*
SGRQ activity 53.3  29.9 48.6  22.0 0.4585
SGRQ impact 34.4  20.7 26.3  21.7 0.1414
COPDZ chronic obstructive pulmonary disease; FEV1Z forced
expiratory volume in 1 second; MMRC Z Modified Medical
Research Council; SGRQ Z Saint George’s Respiratory
Questionnaire.
* Significant difference between reference and investigating
groups.function and global status. In previous studies, patients
with COPD had a decline in FEV1 (31  48 mL/year) after
quitting smoking compared with those who continued to
smoke (62  55 mL/year).16 Although the obstructive
ventilatory defect was irreversible in our patient group, the
decline in FEV1 was only 1.6  21.6 mL/year after a period
of 15 years. Increased lung volume was found in the follow-
up spirometry of our participants but the reason was not
clear. Possible explanations included the resolution of the
interstitial injury or improved air-trapping after the acute
stage, but more data such as residual volume measurement
may be needed for further confirmation. There was no
significant difference in the change of the BMI during the
observational period, indicating that the change in
spirometry was independent of body weight change.
The MMRC dyspnea scale and SGRQ questionnaires were
used for evaluation of the current quality of life in our
patient group and comparison with the reference group.
Age and severity of obstructive ventilation were matched.
Most of our patients with S. androgynus-related obstructive
lung disease were women and they had few co-morbidities.
To reduce the interference of co-comorbidites with quality
of life, we excluded reference patients with a Charlson
index higher that 2 to avoid any impact of co-morbidities on
life quality. Analysis of the SGRQ data showed a significant
difference in symptom scores between groups, suggesting
lower rates of productive cough and breathlessness in the
patient group than in the reference group. The MMRC scale
also indicated better functioning in the patient group,
suggesting less limitation of activities of daily living. This
scale focuses primarily on dyspnea that occurs during
walking and is widely used in patients with COPD because it
correlates with prognosis.17 We supposed that the causative
factors that result in the difference in dyspnea grade or
quality of life may be due to the different pathogenesis in
these two obstructive lung diseases. COPD patients had
chronic airway inflammation and also systemic inflamma-
tion, which resulted in more extrapulmonary symptoms.
Unlike COPD patients, patients with S. androgynus-induced
obstructive lung disease suffered from acute inflammation
and an acute rapid deterioration of lung function within
several months after consumption. After the acute event
and discontinuation of the consumption, no chronic
inflammation persisted, and these patients got stable
pulmonary function in the follow-up course with gradual
adaptation of their physical conditions. To our knowledge,
the 5-year mortality rate of patients with moderate-to-
severe COPD varies from 40% to 70%, depending on
disease severity.18 This also implied consistently less
severity on the MMRC scale and a lower mortality rate in our
patients with S. androgynus-induced obstructive pulmonary
disease.
There were some limitations to this study. First, all-
cause mortality was 8.2% (N Z 4/49) in our study, but this
could be underestimated as 20 patients were not available
for contact and their status was unknown. Second, most of
the patients with S. androgynus-related obstructive lung
disease were women. Gender differences19,20 should be
considered in interpretation of the health status of patients
with COPD and S. androgynus-related obstructive lung
disease. Third, the number of cases analyzed in our study
was relatively small because of the rarity of S. androgynus-
Table 5 Comparison of demographic characteristics and
pulmonary function between follow-up and lost follow-up
cases.
Follow-up
cases
(nZ16)
Lost follow-up
cases
(nZ28)
p value
Age (y) 47.9  7.6 46.2  10.1 0.37
Sex (M/F) 1/15 2/26 0.91
BMI 26.6  5.6 25.7  3.8 0.98
SpO2 (%) 94.2  3.7 95.3  2.2 0.46
Total amounts
(g)
5681.3  3285.4 5592.9  4526.4 0.43
TLC% predicted 94.8  20.3 95.0  12.3 0.80
FEV1/FVC (%) 51.4  10.6 49.8  13.1 0.46
FEV1 (L) 1.0  0.3 1.0  0.4 0.63
FEV1% predicted 43.9  14.1 42.4  18.9 0.69
FVC (L) 2.0  0.7 1.9  0.5 0.73
FVC% predicted 74.6  19.9 71.8  17.8 0.63
BMI Z body mass index; TLC Z total lung capacity;
FEV1 Z forced expiratory volume in 1 second; FVC Z forced
vital capacity.
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generalizable to the overall population with this disease. In
order to offset this shortcoming, we further divided our 49
patients into lost follow-up (n Z 28) and follow-up groups
(n Z 16) to compare the original demographic character-
istics and pulmonary function (Table 5), and no significance
was found between these two groups. We speculated that
our conclusion in this study may be expanded to the lost
follow-up group.
In conclusion, our follow- up study revealed that 15
years after an acute deterioration of S. androgynus-related
obstructive lung disease, obstructive ventilatory defects
were stationary, as shown by the only slight change in the
FEV1, despite irreversibility. In addition, our patient group
had a better quality of life than COPD reference patients.
Due to the small sample size of this study, we still need
a further study with a larger sample size to confirm these
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